A-Z> Fc Receptor Proteins
The efficacy of a therapeutic antibody not only depends on the Fab fragment and its binding activity to the target antigen, but also depends on the Fc fragment and its interaction with key Fc receptors. The binding affinity of the Fc fragment towards FcRn (FCGRT&B2M) would predict the antibody’s half-life, while that between the Fc fragment and FcγRIIIa (CD16a) would influence the antibody’s ability to elicit ADCC (antibody dependent cell mediated cytotoxicity). Therefore, candidates must be tested against a panel of receptors during antibody engineering.
ACROBiosystems offers a comprehensive collection of recombinant Fc receptor proteins, including their common variants, to help expedite your mAb development.
To meet the high purity requirement of pharmaceutical applications, our production team perform both SDS-PAGE and HPLC analyses to the Fc receptors for QC purposes. It’s noteworthy that it’s essential to use monomeric Fc receptor, which represents its natural state. The formation of oligomers during production may result in artificially enhanced binding interaction due to avidity effect. To avoid such situation, we have established strict internal control standards of monomer purity by HPLC testing. Only those batches meeting all purity requirements are released.
Fig. 1 The purity of Human Fc gamma RIIA / CD32a (R167) Protein (Cat. No. CDA-H5221) is greater than 95% as determined in a HPLC analysis.
The binding affinity between two molecules can be determined by many methods. However, the studies of Fc interaction are often done by SPR, because traditional ELISA is not appropriate for low affinity receptors such as CD16 and CD32. To assure our Fc receptors deliver expected performance, our QC team use Biacore platform to test our products against reference antibodies. All SPR protocols are available for free.
Fig. 2 Human CD64, His Tag (SPR & BLI verified) (Cat. No. FCA-H52H1) captured on CM5 chip via anti-His antibody can bind Herceptin with an affinity constant of 4.92 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Fig. 3 Immobilized Human FcRn / FCGRT & B2M Heterodimer Protein (Cat. No. FCM-H5286) on CM5 Chip via anti-His antibody, can bind Herceptin with an affinity constant of 0.489 μM as determined in a SPR assay (Biacore T200).
We routinely apply rigorous quality control measures to ensure consistent performance of our product. As shown below, the batch variation among the tested samples is negligible.
Fig. 4 Immobilized Human Fc gamma RIIB / CD32b Protein (Cat. No. CDB-H5228) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 10 μM as determined in a SPR assay (Biacore T200).
We have compared the performance of different batches of CD32b (CDB-H5228) in the same assay, and the software analysis showed that the similarity score was very high, meaning high batch-to-batch consistency.
Fig. 5 Batch consistency of Human Fc gamma RIIB / CD32b (Cat. No. CDB-H5228). The Similarity for different batchs is more than 90%.
The use of biotin labeling can make your assay development much easier. We offer a variety of ready-to-use biotinylated Fc receptors. These proteins are produced using our in-house developed labeling techniques, which confers high bioactivity and minimal batch-to-batch variation. In addition, we have developed a series of Fc receptors of other species, which are suitable for the screening of non-humanized antibodies or the species cross reaction.
Fig. 6 Biotinylated Human CD16a (V176), His Tag, Avi Tag (Cat. No.CDA-H82E9) captured on Biotin CAP- Series S Sensor Chip can bind Rituximab with an affinity constant of 0.261 μM as determined in a SPR assay (Biacore T200).
Fig. 7 Immobilized Cynomolgus / Rhesus macaque FcRn Protein (Cat. No. FCM-C5284) on CM5 Chip via anti-His antibody, can bind Herceptin with an affinity constant of 0.403 μM as determined in a SPR assay (Biacore T200).
| Molecule | Sign | Species | Tag | |
|---|---|---|---|---|
| FcRn (FCGRT & B2M) | FCM-H5286 | Human | C-6×His | C-Strep II | Request SPR/ BLI Protocol |
| FCM-H8286 | Human | C-6×His | C-Strep II | Request BLI Protocol | |
| FCM-H82W4 (Biotin-labeled) | Human | C-Avi & C-6×His | C-Strep II | Request SPR/ BLI Protocol | |
| FCM-C5284 | Cynomolgus / Rhesus macaque | C-10×His | C-Strep II | Request SPR/ BLI Protocol | |
| FCM-C82W5 (Biotin-labeled) | Cynomolgus / Rhesus macaque | C-Avi & C-10×His | C-Strep II | Request SPR/ BLI Protocol | |
| FCM-M52W2 | Mouse | C-10×His | C-Twin-Strep | Request BLI Protocol | |
| FCM-M82W6 (Biotin-labeled) | Mouse | C-Avi & C-10×His | C-Twin-Strep | Request BLI Protocol | |
| FCM-R5287 | Rat | C-6×His | C-Strep II | Request SPR Protocol | |
| FCM-R82W7 (Biotin-labeled) | Rat | C-Avi & C-10×His | C-Strep II | Request SPR Protocol | |
| FCN-B82W3 (Biotin-labeled) | Bovine | C-10×His & C-Avi | Native | Request SPR Protocol | |
| FCN-F82W3 (Biotin-labeled) | Feline | C-10×His & C-Avi | Native | Request SPR Protocol | |
| FCM-P5280 | Porcine | C-6×His | C-Strep II | Request SPR Protocol | |
| FCM-M82W5 (Biotin-labeled) | Mouse | C-10×His & C-Avi | Native | Request BLI Protocol | |
| FCM-M52W8 | Mouse | C-10×His | Native | Request BLI Protocol | |
| FCM-C82W3 (Biotin-labeled) | Cynomolgus / Rhesus macaque | C-10×His & C-Avi | Native | Request SPR Protocol | |
| FCM-C52W9 | Cynomolgus / Rhesus macaque | C-10×His | Native | Request SPR/ BLI Protocol | |
| FCN-H52W7 | Human | C-10×His | Native | Request SPR/ BLI Protocol | |
| Fc gamma RIIIA / CD16a (F176) | CDA-H5220 | Human | C-10×His | Request SPR/ BLI Protocol |
| CDA-H82E8 (Biotin-labeled) | Human | C-Avi & C-10×His | Request SPR/ BLI Protocol | |
| Fc gamma RIIIA / CD16a (V176) | CD8-H52H4 | Human | C-10×His | Request SPR/ BLI Protocol |
| CDA-H82E9 (Biotin-labeled) | Human | C-Avi & C-10×His | Request SPR/ BLI Protocol | |
| Fc gamma RIIIB / CD16b (NA1) | CDB-H5227 | Human | C-10×His | Request SPR/ BLI Protocol |
| CDB-H82E4 (Biotin-labeled) | Human | C-10×His & C-Avi | Request SPR/ BLI Protocol | |
| Fc gamma RIIIB / CD16b (NA2) | CDB-H5222 | Human | C-10×His | Request SPR/ BLI Protocol |
| CDB-H82Ea (Biotin-labeled) | Human | C-10×His & C-Avi | Request SPR/ BLI Protocol | |
| Fc gamma RIII / CD16 | FC6-C52H9 | Cynomolgus | C-10×His | Request SPR/ BLI Protocol |
| FC6-C82E0 (Biotin-labeled) | Cynomolgus | C-10×His & C-Avi | Request SPR/ BLI Protocol | |
| CDA-M52H8 | Mouse | C-10×His | Request SPR/ BLI Protocol | |
| FC6-R52H6 | Rhesus macaque | C-10×His | ||
| Fc gamma RIIA / CD32a | CDA-R52H4 | Rhesus macaque | C-10×His | |
| CDA-C52H7 | Cynomolgus | C-10×His | Request SPR/ BLI Protocol | |
| CDA-C82E5 (Biotin-labeled) | Cynomolgus | C-10×His & C-Avi | Request SPR/ BLI Protocol | |
| Fc gamma RIIA / CD32a (H167) | CD1-H5223 | Human | C-9×His | Request SPR/ BLI Protocol |
| CDA-H82E6 (Biotin-labeled) | Human | C-Avi & C-10×His | Request SPR/ BLI Protocol | |
| Fc gamma RIIA / CD32a (R167) | CDA-H5221 | Human | C-9×His | Request SPR/ BLI Protocol |
| CDA-H82E7 (Biotin-labeled) | Human | C-Avi & C-10×His | Request SPR/ BLI Protocol | |
| Fc gamma RIIB / CD32b | CDB-H5228 | Human | C-8×His | Request SPR/ BLI Protocol |
| CDB-H82E0 (Biotin-labeled) | Human | C-Avi & C-10×His | Request SPR/ BLI Protocol | |
| CDB-M52H7 | Mouse | C-10×His | Request SPR/ BLI Protocol | |
| CDB-C82E4 (Biotin-labeled) | Cynomolgus | C-10×His & C-Avi | Request SPR Protocol | |
| CDB-M82E8 (Biotin-labeled) | Mouse | C-Avi & C-10×His | Request SPR/ BLI Protocol | |
| Fc gamma RI / CD64 | FCA-C82E8 (Biotin-labeled) | Cynomolgus | C-10×His & C-Avi | Request BLI Protocol |
| CD4-M5227 | Mouse | C-10×His | Request SPR/ BLI Protocol | |
| FCA-H82E8 (Biotin-labeled) | Human | C-10×His & C-Avi | Request SPR/ BLI Protocol | |
| FCA-H52H1 | Human | C-10×His | Request SPR/ BLI Protocol | |
| CD23 | CD3-H5249 | Human | N-10×His | |
| CD3-H82Q5 (Biotin-labeled) | Human | N-10×His & N-Avi |
Authors: Li Zhou et al.
Journal: Biomaterials 2017
Product: Human FcRn（Cat. No.FCM-H5286）
Application: SPR
This web search service is supported by Google Inc.
